"We are constantly looking for ways to make outsourcing easier for our clients and feel this expansion will help streamline the path to the clinic," stated J. Jeff Schwegman, Ph.D., Founder and CEO.
Bloomington, Indiana (PRWEB) September 21, 2016
AB BioTechnologies, Inc., a privately-held pharmaceutical contract service provider, announced today it is expanding its services to include Pre-Clinical manufacturing at its Bloomington, Indiana facility.
New drug candidates must undergo pre-clinical studies to establish a toxicology profile and asses the safety, efficacy and bioactivity prior to filing an Investigation New Drug (IND) application. AB BioTechnologies has the capabilities and experience to perform the early-stage development work (formulation, process, and analytical) through Good Laboratory Practice (GLP) manufacturing to support Pre-Clinical / Toxicology studies. Whether the project is a large or small molecule, liquid or lyophilized, vial or syringe, AB BioTechnologies has the expertise to take a project from concept to clinic.
J. Jeff Schwegman, Ph.D., Founder and CEO, states, “AB BioTechnologies is excited to announce our newest service offering, GLP manufacturing. This is a natural progression for our company, given our existing pharmaceutical development capabilities. We are constantly looking for ways to make outsourcing easier for our clients and feel this expansion will help streamline the path to the clinic.”
AB BioTechnologies will perform GLP manufacturing at their existing facility. Implementation of processes is underway and they anticipate successful completion of a third-party audit by the end of Q3 2016.
About AB BioTechnologies, Inc.
AB BioTechnologies, Inc. is a contract service provider located in Bloomington, Indiana, providing pharmaceutical development services. AB BioTechnologies offers lyophilization cycle and process development services for injectable drugs, diagnostics, and tissue products. In conjunction with these services, AB BioTechnologies offers analytical and formulation development for large and small molecule, emulsions, suspensions, and oral solutions. The company was founded in February 2008 by J. Jeff Schwegman, Ph.D., as a teaching and consulting firm. Since then, AB BioTechnologies has quickly grown, expanding services and laboratory space, to keep up with client demand. For more information, visit us at http://www.ab-biotech.com.